Abstract: The present disclosure provides compounds according to Formula (I), wherein X, R2, R3, R4, and R5 are defined herein. Further disclosed herein are pharmaceutical compositions, orally administrable dosage forms, and methods for using such compounds in the treatment of various diseases and disorders including inflammation, autoimmune disorders, chronic pain and cancer. In particular embodiments, the present disclosure provides orally bioavailable compounds capable of selectively modulating an activity (e.g., inhibition) of the serine/threonine protein kinase TAK1 and/or related kinases.

Abstract: Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

Abstract: Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.

Abstract: Compounds having the general structure A-L-B are presented wherein A and B are independently an E3 ubiquitin ligase protein binding ligand compound of formula 1A or 1B. Pharmaceutical compositions comprising these compounds and methods of use are also presented.